[pubmed] Leflunomide ameliorates experimental autoimmune myasthenia gravis by regulating humoral and cellular immune res
Posté : 08 févr. 2021 12:00
Int Immunopharmacol. 2021 Feb 5;93:107434. doi: 10.1016/j.intimp.2021.107434. Online ahead of print.
ABSTRACT
Leflunomide, an immunosuppressive disease-modifying anti-rheumatic drug (DMARD), is widely used in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PA) as well as multiple sclerosis. However, its role in myasthenia gravis (MG) has not yet been clearly explored. Here, we investigated the effect of leflunomide on experimental autoimmune myasthenia gravis (EAMG) in vivo and in vitro. The results demonstrated that leflunomide alleviated the severity of EAMG associated with reduced serum total anti-acetylcholine receptor (AChR) IgG levels. During the development of EAMG, the increase of follicular helper T cells (Tfh) 1, Tfh 17 cells and decrease of follicular regulatory T cells (Tfr) were reversely altered after leflunomide administration. Our work further found that leflunomide might inhibit Tfh cells through the IL-21/STAT3 pathway to reduce the secretion of antibodies by B cells. In addition, leflunomide rebuilt the balance of Th1/Th2/Th17/Treg subsets. These results suggested that leflunomide ameliorated EAMG severity by regulating humoral immune responses and Th cell profiles thereby providing a novel effective treatment strategy for MG.
PMID:33556668 | DOI:10.1016/j.intimp.2021.107434
Source: https://pubmed.ncbi.nlm.nih.gov/3355666 ... 9&v=2.14.2